36 related articles for article (PubMed ID: 33187810)
1. Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis.
Zhang KD; Jost E; Panse J; Herwartz R; Lindemann-Docter K; Jonigk D; Kricheldorf K; Köchel A; Sauerbrunn N; Brümmendorf TH; Koschmieder S; Isfort S
Ann Hematol; 2024 Apr; 103(4):1149-1158. PubMed ID: 38336973
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma.
Ramalingam TR
Leuk Lymphoma; 2024 Mar; ():1-2. PubMed ID: 38486446
[No Abstract] [Full Text] [Related]
3. Harnessing lymphoma epigenetics to improve therapies.
Yang H; Green MR
Blood; 2020 Nov; 136(21):2386-91. PubMed ID: 33206943
[TBL] [Abstract][Full Text] [Related]
4. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S; Simonova M; Spicka I; Pour L; Kriachok I; Gavriatopoulou M; Pylypenko H; Auner HW; Leleu X; Doronin V; Usenko G; Bahlis NJ; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Gironella M; Jurczyszyn A; Robak P; Galli M; Wallington-Beddoe C; Radinoff A; Salogub G; Stevens DA; Basu S; Liberati AM; Quach H; Goranova-Marinova VS; Bila J; Katodritou E; Oliynyk H; Korenkova S; Kumar J; Jagannath S; Moreau P; Levy M; White D; Gatt ME; Facon T; Mateos MV; Cavo M; Reece D; Anderson LD; Saint-Martin JR; Jeha J; Joshi AA; Chai Y; Li L; Peddagali V; Arazy M; Shah J; Shacham S; Kauffman MG; Dimopoulos MA; Richardson PG; Delimpasi S
Lancet; 2020 Nov; 396(10262):1563-1573. PubMed ID: 33189178
[TBL] [Abstract][Full Text] [Related]
5. Treatment selection and survival outcomes in Early-Stage peripheral T-Cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy?
Rodríguez-López JL; Patel AK; Balasubramani GK; Glaser SM; Beriwal S; Vargo JA
Leuk Lymphoma; 2021 Mar; 62(3):538-548. PubMed ID: 33251899
[TBL] [Abstract][Full Text] [Related]
6. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Harris LJ; Patel K; Martin M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
[TBL] [Abstract][Full Text] [Related]
8. Developments over the last 60 years in diffuse large B-cell lymphomas.
Linch D
Br J Haematol; 2020 Nov; 191(4):552-557. PubMed ID: 33190261
[TBL] [Abstract][Full Text] [Related]
9. Flow Cytometry: From Experimental Design to Its Application in the Diagnosis and Monitoring of Respiratory Diseases.
Flores-Gonzalez J; Cancino-Díaz JC; Chavez-Galan L
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266385
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry to detect bone marrow involvement by follicular lymphoma.
Aren M; Marce S; Jurado R; Tapia G; Puigdefabregues L; Raya M; Cortes M; Garcia-Caro M; Junca J; Mozas P; Viñets E; Cabezon M; Plensa E; Miljkovic M; Sancho JM; Navarro JT; Zamora L; Sorigue M
Cytometry B Clin Cytom; 2022 Nov; 102(6):427-439. PubMed ID: 36314855
[TBL] [Abstract][Full Text] [Related]
11. Role of high acquisition flow cytometry in the detection of marrow involvement in patients with extramedullary B cell non-Hodgkins lymphoma: a comparison with marrow aspirate cytology, trephine biopsy, and PET.
Ramalingam TR; Muthu A; Lakshmanan A; Narla S; Subramanyan A; Simon S; Govindaraj J; Vaidhyanathan L; Easow J; Raja T
Leuk Lymphoma; 2022 Nov; 63(11):2589-2596. PubMed ID: 35819878
[TBL] [Abstract][Full Text] [Related]
12. Prediction Model of Bone Marrow Infiltration in Patients with Malignant Lymphoma Based on Logistic Regression and XGBoost Algorithm.
Huang Y; Chen C; Miao Y
Comput Math Methods Med; 2022; 2022():9620780. PubMed ID: 35799653
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens.
Wang W; Li Y; Ali H; Zhao L; Mei D; Hu W; Jiang B
BMC Cancer; 2021 Dec; 21(1):1315. PubMed ID: 34879826
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry.
Sorigue M; Cañamero E; Miljkovic MD
Blood Rev; 2021 May; 47():100778. PubMed ID: 33187810
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic and prognostic values of flow cytometry in diffuse large B-cell lymphoma with bone marrow involvement].
Hong Y; Wan WL; Li M; Wang H; Dong F; Jing HM; Ke XY; Zhu MX
Zhonghua Yi Xue Za Zhi; 2023 Aug; 103(29):2258-2265. PubMed ID: 37544763
[No Abstract] [Full Text] [Related]
16. A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders.
Sah SP; Matutes E; Wotherspoon AC; Morilla R; Catovsky D
J Clin Pathol; 2003 Feb; 56(2):129-32. PubMed ID: 12560392
[TBL] [Abstract][Full Text] [Related]
17. Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement in B-cell lymphoma.
Gomyo H; Shimoyama M; Minagawa K; Yakushijin K; Urahama N; Okamura A; Yamamoto K; Ito M; Chihara K; Hayashi Y; Matsui T
Haematologica; 2003 Dec; 88(12):1358-65. PubMed ID: 14687988
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma.
Adams HJ; Nievelstein RA; Kwee TC
Blood Rev; 2015 Nov; 29(6):417-25. PubMed ID: 26113144
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
